Is cefalexin more effective than amoxicillin‑clavulanate for managing acute bacterial sinusitis?

No, cefalexin is NOT better than co-amoxiclav for managing sinusitis

Co-amoxiclav (amoxicillin-clavulanate) is the recommended first-line antibiotic for acute bacterial rhinosinusitis (ABRS) in both adults and children, while cefalexin is not indicated for sinusitis treatment at all. 1, 2

Guideline-Based Recommendations

The most authoritative evidence comes from established clinical practice guidelines:

Primary Treatment Choice

• The 2025 AAO-HNS guideline explicitly changed its recommendation to "amoxicillin, with or without clavulanate" as first-line therapy 2, representing the most current expert consensus
• The 2012 IDSA guideline recommends amoxicillin-clavulanate over amoxicillin alone for ABRS in adults (weak recommendation, low-quality evidence) and in children (strong recommendation, moderate-quality evidence) 1
• High-dose amoxicillin-clavulanate (2g twice daily in adults or 90 mg/kg/day twice daily in children) is specifically recommended for initial empiric therapy 1

Cefalexin's Role (or Lack Thereof)

Cefalexin is NOT FDA-approved for sinusitis treatment. The FDA label for cefalexin lists respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes, but explicitly does NOT include sinusitis as an indication 3. The label covers otitis media, skin infections, bone infections, and genitourinary infections—but sinusitis is conspicuously absent.

Supporting Research Evidence

Recent high-quality studies reinforce guideline recommendations:

Co-amoxiclav vs Amoxicillin Comparison

• A 2026 JAMA study (n=234,608 propensity-matched patients) found no difference in treatment failure between amoxicillin-clavulanate and amoxicillin alone (3.0% vs 3.1%), though amoxicillin-clavulanate had higher rates of secondary yeast infections and C. difficile 4
• A 2026 retrospective Israeli study (n=38,810) showed no significant difference in treatment failure between amoxicillin and amoxicillin-clavulanate in patients with comorbidities 5

Limited Cefalexin Data

• Only one dated study from 1985 (n=69) evaluated cefalexin for maxillary sinusitis, showing 83% satisfactory results 6—but this predates modern guidelines and lacks comparison to current standard therapy
• A 2024 Indian dental infection study compared cefalexin-clavulanic acid to co-amoxiclav, showing similar effectiveness 7, but this addressed dental infections, not sinusitis

Clinical Algorithm

For uncomplicated ABRS:

1. First-line: Amoxicillin-clavulanate 875-125 mg twice daily (adults) or high-dose 2g twice daily for severe cases 1, 2
2. Duration: 5-7 days in adults; 10-14 days in children 1
3. Alternative consideration: Plain amoxicillin may be reasonable based on 2025 guideline update and recent evidence showing equivalent outcomes 2, 4
4. Cefalexin: Should NOT be used—it lacks FDA approval for this indication and has no supporting guideline recommendations

Important Caveats

• Watchful waiting without antibiotics is now recommended as initial management for ALL patients with uncomplicated ABRS, regardless of severity 2—this represents a major shift from prior guidelines
• Neither guideline mentions cefalexin as an alternative agent for ABRS
• The 2025 guideline emphasizes that antibiotics should only be initiated after appropriate diagnostic criteria are met (symptoms >10 days, severe symptoms ≥3-4 days, or worsening after initial improvement) 2
• Routine coverage for MRSA is NOT recommended during initial empiric therapy 1

Bottom line: Use co-amoxiclav or amoxicillin for ABRS when antibiotics are indicated. Cefalexin has no role in sinusitis management.